HypoPet AG was founded in 2013 as a spin-off company from the University of Zürich Switzerland. In November that year, HypoPet’s innovative proposal to make cats hypoallergenic by vaccination won the Swiss Innovation Forum’s prestigious Swiss Technology Award. In December 2013 the company was awarded a Research and Development Grant from the Swiss Commission for Technology and Innovation. In September 2014, a further step toward the development of HypoPet’s novel idea was taken when it entered into a commercialization, manufacture, and distribution agreement with the U.K. based company Benchmark Holdings PLC. In May 2017 HypoPet AG and Saiba Animal Health GmbH merged into today's HypoPet AG with its extended drug pipeline of therapeutic vaccines addressing major unmet needs in veterinary medicine.